Effect of Macrolide Exposure on Tailored Helicobacter pylori Eradication Therapy and Antibiotic Resistance Profiles: A Prospective Study Using the Drug Utilization Review System
Helicobacter · 2024
DOI: 10.1111/hel.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Helicobacter, 2024. Verfasst von Jin Hee Noh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Macrolides, Anti-Bacterial Agents, Helicobacter pylori. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Korean College of Helicobacter and Upper Gastrointestinal Research Foundation Grant.
Abstract (Originalsprache)
Background/Aims Determining antibiotic use history accurately is challenging due to its reliance on patient recall. By determining macrolide exposure using the Korean drug utilization review (DUR) system, we analyzed the impact of previous macrolide use on antibiotic resistance profiles and compared the eradication rate between tailored therapy based on macrolide exposure history and empirical therapy.
Methods
Patients with confirmed Helicobacter pylori ( H. pylori ) infection who agreed to access prescription information using the Health Insurance Review and Assessment Service DUR system were enrolled between 2021 and 2023. Patients received tailored therapy, which was clarithromycin (CLR)‐based triple therapy in cases without macrolide exposure and bismuth quadruple (BQ) therapy in cases with macrolide exposure. The empirical therapy group was prospectively recruited at the same time to compare the eradication rate.
Results
A total of 418 patients (tailored therapy group, n = 57; empirical therapy group, n = 361) were analyzed. Among the tailored therapy group, 24.6% took macrolide antibiotics for the past 5 years. CLR resistance rates were higher in patients with previous macrolide use than in those without (66.7% vs. 7.5%, p < 0.001). The tailored therapy group showed a higher eradication rate than the empirical therapy group for intention‐to‐treat (ITT), modified intention‐to‐treat (MITT), and per‐protocol (PP) analyses (ITT, 86.0% vs. 75.6%; MITT, 94.2% vs. 80.3%; PP, 94.2% vs. 85.1%).
Conclusions
Previous macrolide exposure identified using the DUR system was associated with a higher rate of CLR resistance. Tailored therapy based on macrolide exposure history led to higher eradication rates compared to empirical therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
- Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
ORCID-Profile: Jin Hee Noh, Jeong Hoon Lee
Förderung
- Korean College of Helicobacter and Upper Gastrointestinal Research Foundation Grant
Zitieren
APA
Noh, J. H., Choi, K. D., Na, H. K., Ahn, J. Y., Lee, J. H., Jung, K. W., Kim, D. H., Song, H. J., Lee, G. H., & Jung, H. Y. (2024). Effect of Macrolide Exposure on Tailored Helicobacter pylori Eradication Therapy and Antibiotic Resistance Profiles: A Prospective Study Using the Drug Utilization Review System. Helicobacter. https://doi.org/10.1111/hel.70003
Vancouver
Noh JH, Choi KD, Na HK, Ahn JY, Lee JH, Jung KW, et al. Effect of Macrolide Exposure on Tailored Helicobacter pylori Eradication Therapy and Antibiotic Resistance Profiles: A Prospective Study Using the Drug Utilization Review System. Helicobacter. 2024. doi:10.1111/hel.70003
BibTeX
@article{Noh2024,
author = {Noh, Jin Hee and Choi, Kee Don and Na, Hee Kyong and Ahn, Ji Yong and Lee, Jeong Hoon and Jung, Kee Wook and Kim, Do Hoon and Song, Ho June and Lee, Gin Hyug and Jung, Hwoon-Yong},
title = {Effect of Macrolide Exposure on Tailored Helicobacter pylori Eradication Therapy and Antibiotic Resistance Profiles: A Prospective Study Using the Drug Utilization Review System},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.70003}
}
EUVIMED